Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Ȳȭ¼ö¼Ò¿¡ Áý´Ü ³ëÃâµÇ¾î Ä¡·áÇÑ È¯Àڵ鿡 ´ëÇÑ ÀÓ»ó º¸°í¿Í ¹®Çå °íÂû Clinical report and literature review on patients treated with group exposure to hydrogen sulfide

´ëÇÑÀÀ±ÞÀÇÇÐȸÁö 2020³â 31±Ç 1È£ p.17 ~ 22
±è¹Î¼ö, °­ÁöÈÆ, ±è¾ç¿ø, ¹Úâ¹Î, ¹Úöȣ, À±À¯»ó, ÁöÀ籸,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¹Î¼ö ( Kim Min-Su ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç

°­ÁöÈÆ ( Kang Ji-Hun ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç
±è¾ç¿ø ( Kim Yang-Weon ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç
¹Úâ¹Î ( Park Chang-Min ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç
¹Úöȣ ( Park Chul-Ho ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç
À±À¯»ó ( Yoon Yoo-Sang ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç
ÁöÀ籸 ( Ji Jae-Gu ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ÀÀ±ÞÀÇÇб³½Ç

Abstract


Objective: This study examined the clinical manifestations, treatment, and prognostic factors of hydrogen sulfide intoxication.

Method: Twelve cases of hydrogen sulfide leaking from a wastewater treatment company in Sasang-gu, Busan were reviewed. The demographic characteristics, initial symptoms, treatment, complications, and long-term prognosis were reviewed. The Life Science Ethics Review Committee approved this study.

Results: The majority of the 12 cases were male (83%) with an average age of 38 years. Three of the 12 cases, who had been exposed to hydrogen sulfide, died (25%), and four had poor outcomes (33%). The incidence of pulmonary edema was significantly higher in the poor prognosis group, but the incidence of conjunctivitis and pre-hospital cardiac arrest was similar. The lactic acid concentration in the poor prognosis group was higher than the good prognosis group. In the poor prognosis group, the Glasgow coma scale was lower than that in the good prognosis group.

Conclusion: A poor outcome occurred in 33% of the 12 people exposed to hydrogen sulfide in Busan 2018. In the poor outcome group, the initial Glasgow Coma Scale was lower, the pulmonary edema rate and the initial serum lactate level were higher than in the good outcome group.

Å°¿öµå

Hydrogen sulfide; Occupational injuries; Brain injuries

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS